What is claimed is:

1. A compound having the formula



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R^1 is -C_1-C_6 alkyl, aryl, -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')$_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl, with the proviso that when n is 2, R^1 cannot be -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle,

m is an integer ranging from 1-10; and

n is an integer ranging from 1-10.

2. The compound of claim 1 wherein R^1 is phenyl.

3. The compound of claim 1 wherein n is an integer ranging from 1-5.

4. The compound of claim 1 wherein m is 2.

5. The compound of claim 1 wherein R^1 is phenyl, m is 2 and n is 3.

6. The compound of claim 1 wherein R^1 is -4-N(CH_3)$_2$-phenyl and m is 1.

7. The compound of claim 1 wherein R^1 is -4-N(CH_3)$_2$-phenyl, m is 1 and n is 4.

8. The compound of claim 1 wherein R^1 is -4-N(CH_3)$_2$-phenyl, m is 1 and n is 5.

9. A compound having the formula



(II)

or a pharmaceutically acceptable salt thereof,

wherein

Y is $-C(O)CH_2SH$ or $-NHC(O)CH_2SH$;

R^2 is $-C_1$-C_6 alkyl, aryl, $-C_3$-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, $-C_1$-C_6 alkyl, $-O-(C_1$-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', $N(R')_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted $-C_1$-C_6 alkyl;

m is an integer ranging from 0-10; and

n is an integer ranging from 1-10.

10. The compound of claim 9 wherein m is 1.

11. The compound of claim 9 wherein R^2 is $-4-N(CH_3)_2$-phenyl.

12. The compound of claim 9 wherein m is 1 and R^2 is $-4-N(CH_3)_2$-phenyl.

13. A compound having the formula



(III)

or a pharmaceutically acceptable salt thereof,

wherein

Z is $-C(O)NHOH$, $-C(O)CH_2SH$ or $-NHC(O)CH_2SH$;

R^3 is $-C_1$-C_6 alkyl, aryl, $-C_3$-C_7 cycloalkyl, -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, $-C_1$-C_6 alkyl, $-O-(C_1$-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', $N(R')_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted $-C_1$-C_6 alkyl;

R^4 is -H or -Si(R^5)$_3$;

each occurrence of R^5 is independently -C_1-C_6 alkyl;

m is an integer ranging from 0-10; and

n is an integer ranging from 1-10.

14. The compound of claim 13 wherein m is 2.

15. The compound of claim 13 wherein n is 2 or 3.

16. The compound of claim 13 wherein R^3 is phenyl, m is 2, n is 2 and R^4 is -H.

17. The compound of claim 13 wherein R^3 is phenyl, m is 2, n is 3 and R^4 is -H.

18. A compound having the formula



(IV)

or a pharmaceutically acceptable salt thereof,

wherein

R^6 is -C_1-C_6 alkyl, aryl, -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')$_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl;

m is 1 or an integer ranging from 8-10; and

n is an integer ranging from 1-10.

19. A compound having the formula



(V)

or a pharmaceutically acceptable salt thereof,

wherein

Y is -C(O)CH_2SH or -NHC(O)CH_2SH;

R^7 is -C_1-C_6 alkyl, aryl, -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')$_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl; with the proviso that when n is 2, R^7 cannot be -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle;

m is an integer ranging from 0-10; and

n is an integer ranging from 1-10.

20. A compound having the formula



(VI)

or a pharmaceutically acceptable salt thereof,

wherein

each Z is independently -C(O)NHOH, -C(O)CH_2SH or -NHC(O)CH_2SH, with the proviso that when both Z groups are -C(O)NHOH, the phenyl group of said compound of formula (VI) is either ortho or meta substituted;

m is an integer ranging from 1-10; and

n is an integer ranging from 1-10.

21. The compound of claim 20 wherein m is 6, n is 6, the phenyl ring is ortho substituted, and each occurrence of Z is -C(O)NHOH.

22. A compound having the formula



(VII)

or a pharmaceutically acceptable salt thereof,

wherein

each Y is independently -C(O)CH_2SH or -NHC(O)CH_2SH;

m is an integer ranging from 1-10; and

n is an integer ranging from 1-10.

23. A compound having the formula



(VIII)

or a pharmaceutically acceptable salt thereof,

wherein:

each R^8 is independently -C_1-C_6 alkyl, aryl, -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')$_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl;

each G is independently -NH- or -CH_2-;

each J is independently -NH- or -CH_2-;

each m is independently an integer ranging from 1-10; and

each n is independently an integer ranging from 1-10.

24. The compound of claim 23 where R^8 is phenyl, G is -NH-, J is -NH-, m is 0 and n is 6.

25. The compound of claim 23 wherein R_8 is 4-N(CH_3)$_2$-phenyl, G is -NH-, J is -NH-, m is 1 and n is 6.

26. A compound having the formula



(IX)

or a pharmaceutically acceptable salt thereof,

wherein:

R^9 is phenyl, which can be unsubstituted or substituted with one or more of the following groups: -halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -NO_2, -OH, -CN, -COOR', -OC(O)R', NHR', N(R')$_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl; and

m is an integer ranging from 2-10.

27. The compound of claim 26 where m is 6 and R^9 is -phenyl.

28. The compound of claim 26 where m is 6 and R^9 is -4-N$(CH_3)_2$-phenyl.

29. The compound of claim 26 where m is 5, R^9 is -4-biphenyl.

30. The compound of claim 26 where m is 5 and R^9 is -4-N$(CH_3)_2$-phenyl.

31. The compound of claim 26 where m is 5 and R^9 is -phenyl.

32. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or vehicle.

33. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 9 and a pharmaceutically acceptable carrier or vehicle.

34. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 13 and a pharmaceutically acceptable carrier or vehicle.

35. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 18 and a pharmaceutically acceptable carrier or vehicle.

36. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 19 and a pharmaceutically acceptable carrier or vehicle.

37 A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 20 and a pharmaceutically acceptable carrier or vehicle.

38 A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 22 and a pharmaceutically acceptable carrier or vehicle.

39. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 23 and a pharmaceutically acceptable carrier or vehicle.

40. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 26 and a pharmaceutically acceptable carrier or vehicle.

41. A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, said method comprising contacting said cell with a compound having the formula:



(Ia)

or a pharmaceutically acceptable salt thereof,

wherein

R^{1a} is -C_1-C_6 alkyl, aryl, -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -

halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')$_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl;

m is an integer ranging from 0-10; and

n is an integer ranging from 1-10,

in an amount sufficient to increase the sensitivity of said cell to the cytotoxic effects of radiotherapy.

42. A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, said method comprising contacting said cell with the compound or a pharmaceutically acceptable salt of a compound of claim 9 in an amount sufficient to increase the sensitivity of said cell to the cytotoxic effects of radiotherapy.

43. A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, said method comprising contacting said cell with the compound or a pharmaceutically acceptable salt of a compound of claim 13 in an amount sufficient to increase the sensitivity of said cell to the cytotoxic effects of radiotherapy.

44. A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, said method comprising contacting said cell with a compound having the formula:



(IVa)

or a pharmaceutically acceptable salt thereof,

wherein

R^{6a} is -C_1-C_6 alkyl, aryl, -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')$_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl;

m is an integer ranging from 0-10; and

n is an integer ranging from 2-10,

in an amount sufficient to increase the sensitivity of said cell to the cytotoxic effects of radiotherapy.

45. A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, said method comprising contacting said cell with the compound or a pharmaceutically acceptable salt of a compound of claim 19 in an amount sufficient to increase the sensitivity of said cell to the cytotoxic effects of radiotherapy.

46. A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, said method comprising contacting said cell with the compound or a pharmaceutically acceptable salt of a compound of claim 20 in an amount sufficient to increase the sensitivity of said cell to the cytotoxic effects of radiotherapy.

47. A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, said method comprising contacting said cell with the compound or a pharmaceutically acceptable salt of a compound of claim 22 in an amount sufficient to increase the sensitivity of said cell to the cytotoxic effects of radiotherapy.

48. A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, said method comprising contacting said cell with the compound or a pharmaceutically acceptable salt of a compound of claim 23 in an amount sufficient to increase the sensitivity of said cell to the cytotoxic effects of radiotherapy.

49. A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, said method comprising contacting said cell with the compound or a pharmaceutically acceptable salt of a compound of claim 26 in an amount sufficient to increase the sensitivity of said cell to the cytotoxic effects of radiotherapy.

50. The method of any one of claims 41-49, wherein the cell is an *in vivo* cell.

51. A method for treating cancer, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 1 in an amount sufficient to treat said cancer.

52. A method for treating cancer, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 9 in an amount sufficient to treat said cancer.

53. A method for treating cancer, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 13 in an amount sufficient to treat said cancer.

54. A method for treating cancer, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 18 in an amount sufficient to treat said cancer.

55. A method for treating cancer, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 19 in an amount sufficient to treat said cancer.

56. A method for treating cancer, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 20 in an amount sufficient to treat said cancer.

57. A method for treating cancer, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 22 in an amount sufficient to treat said cancer.

58. A method for treating cancer, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 23 in an amount sufficient to treat said cancer.

59. A method for treating cancer, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 26 in an amount sufficient to treat said cancer.

60. The method of any one of claims 51-59 wherein the subject is a human.

61. The method of any one of claims 51-59 wherein the cancer is Non-Hodgkin's lymphoma, Hodgkin's disease, Ewing's sarcoma, testicular cancer, prostate cancer, larynx cancer, cervical cancer, nasopharynx cancer, breast cancer, colon cancer, pancreatic cancer, head and neck cancer, esophogeal cancer, rectal cancer, small-cell lung cancer, non-small cell lung cancer, brain cancer, or a CNS neoplasm.

62. The method of any one of claims 51-59 further comprising administering to said subject another therapeutic agent or a pharmaceutically acceptable salt thereof.

63. The method of claim 62 wherein the other therapeutic agent is an anticancer agent.

64. A method for treating cancer, said method comprising:

(a) administering to a subject in need thereof, a compound having the formula:



(Ia)

or a pharmaceutically acceptable salt thereof,

wherein

R^{1a} is -C_1-C_6 alkyl, aryl, -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')$_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl;

m is an integer ranging from 0-10; and

n is an integer ranging from 1-10,

in an amount sufficient to sensitize a cancer cell to the cytotoxic effects of radiotherapy; and

(b) administering to said subject an amount of radiotherapy sufficient to treat said cancer.

65. A method for treating cancer, said method comprising:

(a) administering to a subject in need thereof, the compound or a pharmaceutically acceptable salt of the compound of claim 9, in an amount sufficient to sensitize a cancer cell to the cytotoxic effects of radiotherapy; and

(b) administering to said subject an amount of radiotherapy sufficient to treat said cancer.

66. A method for treating cancer, said method comprising:

(a) administering to a subject in need thereof, the compound or a pharmaceutically acceptable salt of the compound of claim 13, in an amount sufficient to sensitize a cancer cell to the cytotoxic effects of radiotherapy; and

(b) administering to said subject an amount of radiotherapy sufficient to treat said cancer.

67. A method for treating cancer, said method comprising:

(a) administering to a subject in need thereof, a compound having the formula:



(IVa)

or a pharmaceutically acceptable salt thereof,

wherein

R^{6a} is -C_1-C_6 alkyl, aryl, -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', $N(R')_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl;

m is an integer ranging from 0-10; and

n is an integer ranging from 2-10,

in an amount sufficient to sensitize a cancer cell to the cytotoxic effects of radiotherapy; and

(b) administering to said subject an amount of radiotherapy sufficient to treat said cancer.

68. A method for treating cancer, said method comprising:

(a) administering to a subject in need thereof, the compound or a pharmaceutically acceptable salt of the compound of claim 19, in an amount sufficient to sensitize a cancer cell to the cytotoxic effects of radiotherapy; and

(b) administering to said subject an amount of radiotherapy sufficient to treat said cancer.

69. A method for treating cancer, said method comprising:

(a) administering to a subject in need thereof, the compound or a pharmaceutically acceptable salt of the compound of claim 20, in an amount sufficient to sensitize a cancer cell to the cytotoxic effects of radiotherapy; and

(b) administering to said subject an amount of radiotherapy sufficient to treat said cancer.

70. A method for treating cancer, said method comprising:

(a) administering to a subject in need thereof, the compound or a pharmaceutically acceptable salt of the compound of claim 22, in an amount sufficient to sensitize a cancer cell to the cytotoxic effects of radiotherapy; and

(b) administering to said subject an amount of radiotherapy sufficient to treat said cancer.

71. A method for treating cancer, said method comprising:

(a) administering to a subject in need thereof, the compound or a pharmaceutically acceptable salt of the compound of claim 23, in an amount sufficient to sensitize a cancer cell to the cytotoxic effects of radiotherapy; and

(b) administering to said subject an amount of radiotherapy sufficient to treat said cancer.

72. A method for treating cancer, said method comprising:

(a) administering to a subject in need thereof, the compound or a pharmaceutically acceptable salt of the compound of claim 26, in an amount sufficient to sensitize a cancer cell to the cytotoxic effects of radiotherapy; and

(b) administering to said subject an amount of radiotherapy sufficient to treat said cancer.

73. The method of any one of claims 64-72 wherein the compound administered in step (a) and the radiotherapy administered in step (b) act adjunctively.

74. The method of any one of claims 64-72 wherein the subject is a human.

75. The method of any one of claims 64-72 wherein the cancer is Non-Hodgkin's lymphoma, Hodgkin's disease, Ewing's sarcoma, testicular cancer, prostate cancer, larynx cancer, cervical cancer, nasopharynx cancer, breast cancer, colon cancer, pancreatic cancer, head and neck cancer, esophogeal cancer, rectal cancer, small-cell lung cancer, non-small cell lung cancer, brain cancer, or a CNS neoplasm.

76. The method of any one of claims 64-72 further comprising administering to said subject another therapeutic agent or a pharmaceutically acceptable salt thereof.

77. The method of claim 76 wherein the other therapeutic agent is an anticancer agent.

78. The method of any one of claims 64-72 wherein the administering of step (a) is done prior to the administering of step (b).

79. The method of any one of claims 64-72 wherein the administering of step (a) is done subsequent to the administering of step (b).

80. The method of any one of claims 64-72 wherein the administering of step (a) and the administering of step (b) are done concurrently.

81. A method for treating a neurological disease, said method comprising administering to a subject in need thereof a compound having the formula



(Ia)

or a pharmaceutically acceptable salt thereof,

wherein

R^{1a} is -C_1-C_6 alkyl, aryl, -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')$_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl;

m is an integer ranging from 0-10; and

n is an integer ranging from 1-10,

in an amount sufficient to treat said neurological disease.

82. A method for treating a neurological disease, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 9 in an amount sufficient to treat said neurological disease.

83. A method for treating a neurological disease, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 13 in an amount sufficient to treat said neurological disease.

84. A method for treating a neurological disease, said method comprising administering to a subject in need thereof a compound having the formula:



(IVa)

or a pharmaceutically acceptable salt thereof,

wherein

R^{6a} is -C_1-C_6 alkyl, aryl, -C_3-C_7 cycloalkyl or -3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo, -C_1-C_6 alkyl, –O-(C_1-C_6 alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')$_2$, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted -C_1-C_6 alkyl;

m is an integer ranging from 0-10; and

n is an integer ranging from 2-10,

in an amount sufficient to treat said neurological disease.

85. A method for treating a neurological disease, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 19 in an amount sufficient to treat said neurological disease.

86. A method for treating a neurological disease, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 20 in an amount sufficient to treat said neurological disease.

87. A method for treating a neurological disease, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 22 in an amount sufficient to treat said neurological disease.

88. A method for treating a neurological disease, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 23 in an amount sufficient to treat said neurological disease.

89. A method for treating a neurological disease, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 26 in an amount sufficient to treat said neurological disease.

90. The method of any one of claims 81-89 wherein said disease of the central nervous system is Huntington's disease, lupus, or schizophrenia.

91. The method of any one of claims 81-89 wherein the subject is a human.